Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.
Selective stock-picking and conviction drove HB Biotech’s strong 2024 performance. Read our insights on navigating today’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback